| Similar Articles |
|---|
 |
The Motley Fool
March 1, 2005
Charly Travers |
From Rags to Riches One biotech's fate reveals the formula for spotting turnaround investments. BioMarin has yet to turn the corner, but that time is quickly approaching.   |
The Motley Fool
May 17, 2005
Charly Travers |
BioMarin Bounces Back After a stumble, one biotech firm is returning to the market's good graces. BioMarin stock has shot up 30% in the past two months and is near its 52-week high. |
The Motley Fool
July 31, 2009
Brian Orelli |
The Little Orphan That Could After a rough start to the year, Rule Breakers pick BioMarin Pharmaceutical is back on track. |
The Motley Fool
November 2, 2006
Brian Lawler |
BioMarin's in Good Health This biopharma has a leg up on the competition by getting its finances in order. Even with its small pipeline, BioMarin appears to be running smoothly. Investors, take note. |
The Motley Fool
August 6, 2008
Brian Lawler |
BioMarin's New Drugs Mostly Hit Their Targets Near-term volatility in a drugmaker's shares can make for long-term opportunities. Such is the current case with BioMarin Pharmaceutical. |
The Motley Fool
April 16, 2004
Charly Travers |
Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out. |
The Motley Fool
April 30, 2008
Brian Lawler |
BioMarin's Bodacious Earnings BioMarin raises revenue guidance for all of its marketed drugs, thanks to strong sales so far in 2008. |
The Motley Fool
August 9, 2007
Brian Lawler |
BioMarin Gets Busy BioMarin Pharmaceutical has a busy remainder of 2007 ahead of it, including regulatory decisions, six clinical trials, and the potential for new products to enter the pipeline. |
The Motley Fool
February 27, 2007
Brian Lawler |
Mostly Good From BioMarin Drugmaker BioMarin updates investors on its drug pipeline and quarterly financial results. |
The Motley Fool
October 29, 2009
Brian Orelli |
Small and Volatile, but Not for Long BioMarin is growing. |
The Motley Fool
April 1, 2008
Brian Lawler |
BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan. |
